Discover how a plasmid DNA manufacturing platform process is helpful from preclinical studies to scaling production for late-stage and commercial needs.
List view / Grid view
The findings provide insight into how genetics can make someone more susceptible to developing PTSD following trauma exposure.
20 October 2022 | By Cytiva
This webinar will share preliminary data demonstrating the promising performance of a new cell culture media specifically developed for T-cell based therapies.
This whitepaper reviews the drug discovery progress for neurodegenerative diseases, focusing on promising candidates identified using iPSC technology.
Learn how you can mobilise CD34+ haematopoietic stem cells and how they can be isolated immediately after collection.
The pipetting robot, flowbot® ONE, is available with UV light to make clean-up processes easy and effective, enabling you to keep your samples safe.
Whitepaper: Disease state primary cells bring verification and validation studies closer to real-world results
Discover how BioIVT’s portfolio of disease state LEUKOMAX® leukopaks and PBMCs can serve as representative starting materials for autologous cell therapy research.
Ensuring that drug candidates can reach the clinic is no easy task, so having models that can closely represent human pathology is crucial. Here, Dr Beth Hoffman, CEO of Origami Therapeutics, describes the successes and challenges of using human disease cell models in drug discovery.
Discover how BioIVT’s dissociated tumour cells (DTCs) can be used for tumour-infiltrating lymphocyte (TIL) cell therapy research.
Cellistic has agreed to acquire Celyad Oncology’s Manufacturing Business Unit in Mont-Saint-Guibert, Belgium, for €6 million.
Download this infographic to find out why the method of generating human iPSC-derived cells matters.
Researchers find that mitochondria’s shape transitions as they elongate and divide are in fact regulating the dormant state of adult muscle stem cells.
19 August 2022 | By Sartorius
Want to learn about the latest research and development of cell models in rare diseases? Then watch this virtual panel discussion to hear from industry experts.